Cargando…
MicroRNAs as Indicators of Malignancy in Pancreatic Ductal Adenocarcinoma (PDAC) and Cystic Pancreatic Lesions
The dysregulation of microRNAs has recently been associated with cancer development and progression in pancreatic ductal adenocarcinoma (PDAC) and cystic pancreatic lesions. In solid pancreatic tumor tissue, the dysregulation of miR-146, miR-196a/b, miR-198, miR-217, miR-409, and miR-490, as well as...
Autores principales: | Prinz, Christian, Fehring, Leonard, Frese, Robin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9368175/ https://www.ncbi.nlm.nih.gov/pubmed/35954223 http://dx.doi.org/10.3390/cells11152374 |
Ejemplares similares
-
Overexpression of Mesothelin in Pancreatic Ductal Adenocarcinoma (PDAC)
por: Le, Kai, et al.
Publicado: (2020) -
Modifiable Pancreatic Ductal Adenocarcinoma (PDAC) Risk Factors
por: Michalak, Natalia, et al.
Publicado: (2023) -
Clinically impactful metabolic subtypes of pancreatic ductal adenocarcinoma (PDAC)
por: Pervin, Jannat, et al.
Publicado: (2023) -
The role of survivin in the progression of pancreatic ductal adenocarcinoma (PDAC) and a novel survivin-targeted therapeutic for PDAC
por: Brown, Matthew, et al.
Publicado: (2020) -
ANO1 (TMEM16A) in pancreatic ductal adenocarcinoma (PDAC)
por: Sauter, D. R. P., et al.
Publicado: (2014)